Amphastar Pharmaceuticals (AMPH) Reports Earnings Tomorrow: What To Expect

Amphastar Pharmaceuticals (AMPH) Reports Earnings Tomorrow: What To Expect

Anthony Lee

Thu, February 26, 2026 at 2:41 AM GMT+9 2 min read

In this article:

AMPH

-0.69%

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect.

Amphastar Pharmaceuticals beat analysts’ revenue expectations last quarter, reporting revenues of $191.8 million, flat year on year. It was an exceptional quarter for the company, with a solid beat of analysts’ revenue estimates and a beat of analysts’ EPS estimates.

Is Amphastar Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Amphastar Pharmaceuticals’s revenue to be flat year on year, slowing from the 2.9% increase it recorded in the same quarter last year.

Amphastar Pharmaceuticals Total Revenue

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Amphastar Pharmaceuticals has missed Wall Street’s revenue estimates multiple times over the last two years.

Looking at Amphastar Pharmaceuticals’s peers in the pharmaceuticals segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Eli Lilly delivered year-on-year revenue growth of 42.6%, beating analysts’ expectations by 7.4%, and Bristol-Myers Squibb reported revenues up 1.4%, topping estimates by 4.8%. Eli Lilly traded up 1.7% following the results while Bristol-Myers Squibb was also up 7.6%.

Read our full analysis of Eli Lilly’s results here and Bristol-Myers Squibb’s results here.

Investors in the pharmaceuticals segment have had fairly steady hands going into earnings, with share prices down 1.1% on average over the last month. Amphastar Pharmaceuticals is up 6% during the same time and is heading into earnings with an average analyst price target of $31.57 (compared to the current share price of $27.76).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.

Terms and Privacy Policy

Privacy Dashboard

More Info